Pushing estrogen receptor around in breast cancer.
暂无分享,去创建一个
W. Tilley | T. Hickey | G. Tarulli | N. Portman | E. Lim | C. Palmieri | Theresa E. Hickey
[1] S. Galal,et al. Expression of androgen receptors in primary breast cancer , 2016 .
[2] G. Hortobagyi,et al. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. , 2016, JAMA oncology.
[3] M. Goetz,et al. Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor-Positive Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Dowsett,et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Jason Gertz,et al. Cooperative Dynamics of AR and ER Activity in Breast Cancer , 2016, Molecular Cancer Research.
[6] M. Ellis,et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. , 2016, The Lancet. Oncology.
[7] K. Gelmon,et al. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). , 2016 .
[8] G. Hampton,et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant , 2016, Nature Communications.
[9] M. Zweifel,et al. Abstract P5-14-05: Phase 1 evaluation of the androgen receptor modulator CR1447 in patients with advanced breast cancer (SAKK 21/12) , 2016 .
[10] J. Baselga,et al. Abstract S6-01:PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial: , 2016 .
[11] P. V. van Diest,et al. St. Gallen endocrine response classes predict recurrence rates over time. , 2015, Breast.
[12] P. Neven,et al. Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer† , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] J. Forbes,et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.
[14] R. Schiff,et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer , 2015, Nature Reviews Clinical Oncology.
[15] Matt Trau,et al. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer , 2015, Nature Communications.
[16] C. Hudis,et al. Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). , 2015 .
[17] E. Winer,et al. Abstract P1-13-04: Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival , 2015 .
[18] Myles A Brown,et al. Targeting the Androgen Receptor in Breast Cancer , 2015, Current Oncology Reports.
[19] H. Sasano,et al. The intracrinology of breast cancer , 2015, The Journal of Steroid Biochemistry and Molecular Biology.
[20] P. Neven,et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] J. Dalton,et al. Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer , 2014, Steroids.
[22] Takashi Suzuki,et al. Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma , 2014, The Journal of Steroid Biochemistry and Molecular Biology.
[23] S. Fuqua,et al. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer , 2014, Breast Cancer Research and Treatment.
[24] H. Sasano,et al. Complexities of androgen receptor signalling in breast cancer. , 2014, Endocrine-related cancer.
[25] C. Hudis,et al. 10PA PHASE 1 OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ENZALUTAMIDE ALONE OR COMBINED WITH AN AROMATASE INHIBITOR IN WOMEN WITH ADVANCED BREAST CANCER , 2014 .
[26] R. Dienstmann,et al. Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] Myles A Brown,et al. Importance of Breast Cancer Subtype in the Development of Androgen-Receptor-Directed Therapy , 2014, Current Breast Cancer Reports.
[28] S. Fuqua,et al. Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight , 2014, Breast Cancer Research and Treatment.
[29] A. Thor,et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide , 2014, Breast Cancer Research.
[30] John M S Bartlett,et al. An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.
[31] A. Thompson,et al. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study , 2013, British Journal of Cancer.
[32] David Chen,et al. ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.
[33] Javed Siddiqui,et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.
[34] T. Hitaka,et al. Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys , 2013, The Journal of Steroid Biochemistry and Molecular Biology.
[35] W. Jonat,et al. Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] Takuji Iwase,et al. Clinical importance of androgen receptor in breast cancer patients treated with adjuvant tamoxifen monotherapy , 2013, Breast Cancer.
[37] Andres Forero,et al. Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer , 2013, Clinical Cancer Research.
[38] W. Gerald,et al. Expression of androgen receptor and its phosphorylated forms in breast cancer progression , 2013, Cancer.
[39] R. Coombes,et al. A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer , 2013, Breast Cancer Research and Treatment.
[40] I. Agoulnik,et al. Reduced Androgen Receptor Expression Accelerates the Onset of ERBB2 Induced Breast Tumors in Female Mice , 2013, PloS one.
[41] A. Dobs,et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. , 2013, The Lancet. Oncology.
[42] Carlos Caldas,et al. Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. , 2013, Cell reports.
[43] R. Wirtz,et al. Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers , 2013, Journal of Cancer Research and Clinical Oncology.
[44] M. Ellis,et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study , 2012, Breast Cancer Research and Treatment.
[45] Myles A Brown,et al. Elucidating the role of androgen receptor in breast cancer , 2012 .
[46] Robert B Livingston,et al. Combination anastrozole and fulvestrant in metastatic breast cancer. , 2012, The New England journal of medicine.
[47] G. Buchanan,et al. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. , 2012, Endocrine-related cancer.
[48] I. Ray-Coquard,et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] J. Harrell,et al. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures , 2012, Breast Cancer Research and Treatment.
[50] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[51] P. Argani,et al. Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. , 2012, Human pathology.
[52] J. Carroll,et al. Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? , 2012, Molecular endocrinology.
[53] A. Hill,et al. AIB1:ERα Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor–Resistant Breast Cancer Cells , 2012, Clinical Cancer Research.
[54] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[55] Joshua F. McMichael,et al. Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.
[56] T. Hitaka,et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys , 2012, The Journal of Steroid Biochemistry and Molecular Biology.
[57] M. Sikora,et al. Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation , 2012, Breast Cancer Research and Treatment.
[58] David Handelsman,et al. Androgen Resistance in Female Mice Increases Susceptibility to DMBA-Induced Mammary Tumors , 2012, Hormones and Cancer.
[59] P. Vogt. Cyclin Dependent Kinase , 2011 .
[60] I. Ellis,et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.
[61] J. Cuzick,et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] T. Hitaka,et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. , 2011, Bioorganic & medicinal chemistry.
[63] Mitch Dowsett,et al. Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. , 2011, Journal of the National Cancer Institute. Monographs.
[64] R Peto,et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.
[65] L. Butler,et al. Differential effects of exogenous androgen and an androgen receptor antagonist in the peri- and postpubertal murine mammary gland. , 2011, Endocrinology.
[66] Carsten Denkert,et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy , 2011, Breast Cancer Research and Treatment.
[67] I. Mills,et al. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1 , 2011, The EMBO journal.
[68] J. Dalton,et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial , 2011, Journal of cachexia, sarcopenia and muscle.
[69] R. Dikshit,et al. Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] Harvard Medical School,et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. , 2011, Cancer cell.
[71] Y. Niu,et al. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[72] R. Clarke,et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. , 2011, Endocrine-related cancer.
[73] G. Colditz,et al. Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women , 2011, Clinical Cancer Research.
[74] C. Palmieri,et al. Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer , 2011, Expert review of anticancer therapy.
[75] R. Tamimi,et al. Androgen Receptor Expression in Breast Cancer in Relation to Molecular Phenotype: Results from the Nurses’ Health Study , 2011, Modern Pathology.
[76] J. Carroll,et al. FOXA1 is a critical determinant of Estrogen Receptor function and endocrine response , 2010, Nature Genetics.
[77] F. Sessa,et al. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers , 2010, Virchows Archiv.
[78] G. Viale,et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers , 2010, Breast Cancer Research and Treatment.
[79] Rohit Bhargava,et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation , 2010, Modern Pathology.
[80] J. Cuzick,et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] S. Jick,et al. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations , 2009, Climacteric : the journal of the International Menopause Society.
[82] Li Jia,et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. , 2009, Cancer research.
[83] Ramesh Narayanan,et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. , 2009, Journal of medicinal chemistry.
[84] H. Scher,et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.
[85] M. Sikora,et al. The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance , 2009, Breast Cancer Research and Treatment.
[86] W. Gerald,et al. Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer , 2009, Clinical Cancer Research.
[87] B. Ramaswamy,et al. Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant. , 2009 .
[88] W. Pangborn,et al. Structural basis for androgen specificity and oestrogen synthesis in human aromatase , 2009, Nature.
[89] P. Lønning. Additive endocrine therapy for advanced breast cancer – back to the future , 2009, Acta oncologica.
[90] Duane D. Miller,et al. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. , 2008, Molecular endocrinology.
[91] M. Ewertz,et al. Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C) , 2008, Acta oncologica.
[92] P. Neven,et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] G. Buchanan,et al. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[94] A. León,et al. Androgens and androgen receptors in breast cancer , 2007, Journal of Steroid Biochemistry and Molecular Biology.
[95] F. Clavel-Chapelon,et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study , 2007, Breast Cancer Research and Treatment.
[96] Mitch Dowsett,et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.
[97] M. Espié,et al. Breast cancer incidence and hormone replacement therapy: Results from the MISSION study, prospective phase , 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[98] Vincent Laudet,et al. Overview of Nomenclature of Nuclear Receptors , 2006, Pharmacological Reviews.
[99] W. Gerald,et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen , 2006, Oncogene.
[100] R. Coombes,et al. Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor , 2006, Clinical Cancer Research.
[101] Duane D. Miller,et al. The Para Substituent of S-3-(Phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides Is a Major Structural Determinant of in Vivo Disposition and Activity of Selective Androgen Receptor Modulators , 2005, Journal of Pharmacology and Experimental Therapeutics.
[102] J. Dalton,et al. Discovery and therapeutic promise of selective androgen receptor modulators. , 2005, Molecular interventions.
[103] S. Andò,et al. Endogenous Coactivator ARA70 Interacts with Estrogen Receptor α (ERα) and Modulates the Functional ERα/Androgen Receptor Interplay in MCF-7 Cells* , 2005, Journal of Biological Chemistry.
[104] F. Clavel-Chapelon,et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N‐EPIC cohort , 2005, International journal of cancer.
[105] Paul E Swanson,et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. , 2003, American journal of clinical pathology.
[106] E. Simpson. Sources of estrogen and their importance , 2003, The Journal of Steroid Biochemistry and Molecular Biology.
[107] H. Denk,et al. Androgen receptors frequently are expressed in breast carcinomas , 2003, Cancer.
[108] C. Osborne,et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[109] L. Pinsky,et al. Interactions between androgen and estrogen receptors and the effects on their transactivational properties , 2000, Molecular and Cellular Endocrinology.
[110] P. Lønning. Clinico-pharmacological aspects of different hormone treatments. , 2000, European journal of cancer.
[111] J. Robertson,et al. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. , 1999, European journal of cancer.
[112] E. Eisenhauer,et al. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] D. Horsfall,et al. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] D. Horsfall,et al. Androgens induce divergent proliferative responses in human breast cancer cell lines , 1995, The Journal of Steroid Biochemistry and Molecular Biology.
[115] L. Case,et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] G. Brufman,et al. Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and/or aminoglutethimide. , 1994, Oncology.
[117] W. McGuire,et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[118] D. Schaid,et al. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis , 1991, Cancer.
[119] C. Spurr,et al. High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[120] T. Thorsen,et al. Improved measurement of androgen receptors in human breast cancer. , 1989, Cancer research.
[121] P. Lønning,et al. Megestrol acetate versus aminoglutethimide for metastatic breast cancer , 1989, Breast Cancer Research and Treatment.
[122] M. Dumont,et al. Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. , 1989, Endocrinology.
[123] J. Klijn,et al. Antiprogestins, a new form of endocrine therapy for human breast cancer. , 1989, Cancer research.
[124] P. Canney,et al. Randomized Trial Comparing Aminoglutethimide With High-Dose Medroxyprogesterone Acetate in Therapy for Advanced Breast Carcinomau , 1988 .
[125] C. Redmond,et al. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[126] G. Romieu,et al. The antiprogestin RU486 in advanced breast cancer: Preliminary clinical trial , 1988 .
[127] H. Muss,et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[128] M. Dowsett,et al. 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer , 1987, Steroids.
[129] D. Sleijfer,et al. Oral high‐dose medroxyprogesterone acetate versus tamoxifen: A randomized crossover trial in postmenopausal patients with advanced breast cancer , 1986, Cancer.
[130] S Marsoni,et al. The phase II trial. , 1985, Cancer treatment reports.
[131] M. Dowsett,et al. 4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCER , 1984, The Lancet.
[132] B. Edwards,et al. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. , 1983, Annals of internal medicine.
[133] J. Ingle,et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. , 1982, American journal of clinical oncology.
[134] A. Manni,et al. Androgen‐induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer , 1981, Cancer.
[135] F. Pannuti,et al. A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate. , 1978, Cancer treatment reports.
[136] W. McGuire,et al. Estrogen receptors in androgen-induced breast tumor regression. , 1977, Cancer research.
[137] E. Scarano,et al. DNA Methylation , 1973, Nature.
[138] I. Todd,et al. A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 , 1971, British Journal of Cancer.
[139] B. Stoll. Progestin therapy of breast cancer: comparison of agents. , 1967, British medical journal.
[140] I. S. Goldenberg,et al. Hormonal therapy of metastatic female breast carcinoma. IV. 17β‐amino‐5α‐androstan‐11β‐ol , 1964 .
[141] I. S. Goldenberg,et al. Hormonal therapy of metastatic female breast carcinoma. II. 2α‐methyl dihydrotestosterone propionate , 1961, Cancer.
[142] B. Kennedy. Fluoxymesterone therapy in advanced breast cancer. , 1958, The New England journal of medicine.
[143] B. J. Kennedy. Fluoxymesterone in the treatment of advanced breast cancer , 1957, Cancer.
[144] F. Adair,et al. The use of testosterone propionate in the treatment of advanced carcinoma of the breast. , 1946, Annals of surgery.
[145] M. Dowsett,et al. Plasma ESR 1 Mutations and the Treatment of Estrogen Receptor – Positive Advanced Breast Cancer , 2016 .
[146] Xin Huang,et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.
[147] Massimo Cristofanilli,et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.
[148] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[149] J. Thigpen. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer , 2012 .
[150] Jack Cuzick,et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. , 2008, The Lancet. Oncology.
[151] F. Clavel-Chapelon,et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study , 2008 .
[152] P. Neven,et al. Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198 , 2007 .
[153] C. Gomez-Fernandez,et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. , 2005, American journal of clinical pathology.
[154] W. Tilley,et al. Role of the Androgen Receptor in Human Breast Cancer , 2004, Journal of Mammary Gland Biology and Neoplasia.
[155] D. Berry,et al. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[156] F. Pannuti,et al. High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients. , 1991, Oncology.
[157] P. Canney,et al. Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma. , 1988, Journal of the National Cancer Institute.
[158] D. Ettinger,et al. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response. , 1986, Seminars in oncology.
[159] H. Westerberg. Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial. , 1980, Cancer treatment reports.
[160] I. S. Goldenberg. TESTOSTERONE PROPIONATE THERAPY IN BREAST CANCER. , 1964, JAMA.